Buyer clubs and executive access for Series B companies: scaling without breaking for healthcare and life sciences in the Middle East

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install buyer clubs and executive access has to be shaped to that reality from day one.

Series B is the stress test for buyer clubs and executive access. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, cycle length from first touch to closed-won, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Buyer clubs and executive access is only useful here when it is pointed at both constraints at once.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of buyer clubs and executive access is confusing sponsorship with membership, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on cycle length from first touch to closed-won outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run buyer clubs and executive access function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences in the Middle East: the healthcare teams that install this get past procurement instead of dying in it, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing buyer clubs and executive access deliberately for this market rather than importing a playbook designed for somewhere else.